Summary
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
History
Deltex was established in 1997 as a medical technology company, to develop technologies to measure blood flow. With the successful development of the world’s first Oesophageal Doppler and subsequent research and development, Deltex produced a range of advanced Oesophageal Doppler monitors. Following a period of research and development, with the goal of improving patient outcome, Deltex launched its flagship product, CardioQ-ODM in 2010.
Mission
Our mission is to be a leader in developing and delivering advanced non invasive continuous haemodynamic monitoring systems to improve patient outcomes in cardiovascular disease and surgery.
Vision
Our vision is to be the preferred non-invasive provider for cardiovascular disease and surgery, combining a true commitment to R&D and innovation with a focus on customer service and operational excellence.
Key Team
Mr. Andrew Jonathan Mears (CEO & Director)
Ms. Natalie Emilia Wettler (Group Fin. Director, Company Sec. & Director)
Ms. Marion Lee (HR Director)
Recognition and Awards
Deltex Medical has been awarded numerous awards for its innovative products and technologies including the Queen's Award for Innovation in 2019, and the 'Innovating Britain' Award from the Financial Times in 2020.
References
